SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Cipla - Quaterly Results

13 May 2025 Evaluate
The revenue zoomed 18.86% to Rs. 47978.90 millions for the quarter ended March 2025 as compared to Rs. 40366.60 millions during the corresponding quarter last year.Net profit surges 51.26% to Rs. 14854.00  millions  from Rs. 9820.30 millions in the quarter ended March 2025.Operating profit for the quarter ended March 2025 rose to 16120.80 millions as compared to 13665.00 millions of corresponding quarter ended March 2024.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202503 202403 % Var 202503 202403 % Var 202503 202403 % Var
Sales 47978.90 40366.60 18.86 190448.50 165743.40 14.91 190448.50 165743.40 14.91
Other Income 2933.70 5386.10 -45.53 9847.20 10706.60 -8.03 9847.20 10706.60 -8.03
PBIDT 16120.80 13665.00 17.97 67631.60 55548.10 21.75 67631.60 55548.10 21.75
Interest 34.90 54.50 -35.96 151.10 202.50 -25.38 151.10 202.50 -25.38
PBDT 19032.50 13610.50 39.84 70427.10 55345.60 27.25 70427.10 55345.60 27.25
Depreciation 1477.00 1368.10 7.96 5738.90 5875.90 -2.33 5738.90 5875.90 -2.33
PBT 17555.50 12242.40 43.40 64688.20 49469.70 30.76 64688.20 49469.70 30.76
TAX 2701.50 2422.10 11.54 13111.70 12327.80 6.36 13111.70 12327.80 6.36
Deferred Tax -625.60 20.30 -3181.77 -491.50 60.90 -907.06 -491.50 60.90 -907.06
PAT 14854.00 9820.30 51.26 51576.50 37141.90 38.86 51576.50 37141.90 38.86
Equity 1615.20 1614.70 0.03 1615.20 1614.70 0.03 1615.20 1614.70 0.03
PBIDTM(%) 33.60 33.85 -0.75 35.51 33.51 5.96 35.51 33.51 5.96

Cipla Share Price

1305.85 70.85 (5.74%)
23-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1679.85
Dr. Reddys Lab 1333.05
Cipla 1305.85
Zydus Lifesciences 947.10
Lupin 2340.20
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×